Belzutifan (BioDeep_00000841699)
代谢物信息卡片
化学式: C17H12F3NO4S (383.04391080000005)
中文名称:
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CS(=O)(=O)C1=C2C(C(C(C2=C(C=C1)OC3=CC(=CC(=C3)C#N)F)F)F)O
InChI: InChI=1S/C17H12F3NO4S/c1-26(23,24)12-3-2-11(13-14(12)17(22)16(20)15(13)19)25-10-5-8(7-21)4-9(18)6-10/h2-6,15-17,22H,1H3/t15-,16-,17+/m1/s1
描述信息
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents
D000970 - Antineoplastic Agents
Belzutifan (PT2977) is an orally active and selective HIF-2α inhibitor with an IC50 of 9 nM. Belzutifan, as a second-generation HIF-2α inhibitor, increases potency and improves pharmacokinetic profile. Belzutifan is a potential treatment for clear cell renal cell carcinoma (ccRCC)[1].
同义名列表
3 个代谢物同义名
数据库引用编号
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Qiong Fang, Zhiying Li, Ye Xue, Xin Zong, Wenshuang Ma, Guangmin Xi, XiaoFeng Zhang, Zuowei Li. Embelin enhances the sensitivity of renal cancer cells to axitinib by inhibiting HIF signaling pathway.
Anti-cancer agents in medicinal chemistry.
2022 Aug; ?(?):. doi:
10.2174/1871520622666220825155125. [PMID: 36028958] - Eric Jonasch, Frede Donskov, Othon Iliopoulos, W Kimryn Rathmell, Vivek K Narayan, Benjamin L Maughan, Stephane Oudard, Tobias Else, Jodi K Maranchie, Sarah J Welsh, Sanjay Thamake, Eric K Park, Rodolfo F Perini, W Marston Linehan, Ramaprasad Srinivasan. Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease.
The New England journal of medicine.
2021 11; 385(22):2036-2046. doi:
10.1056/nejmoa2103425. [PMID: 34818478] - Emma D Deeks. Belzutifan: First Approval.
Drugs.
2021 Nov; 81(16):1921-1927. doi:
10.1007/s40265-021-01606-x. [PMID: 34613603] - NULL. The HIF2α Inhibitor Belzutifan Shows Signs of Efficacy in Kidney Cancer.
Cancer discovery.
2021 Jun; 11(6):1319. doi:
10.1158/2159-8290.cd-rw2021-062. [PMID: 33931436] - Elshad Hasanov, Eric Jonasch. MK-6482 as a potential treatment for von Hippel-Lindau disease-associated clear cell renal cell carcinoma.
Expert opinion on investigational drugs.
2021 May; 30(5):495-504. doi:
10.1080/13543784.2021.1925248. [PMID: 33945366] - Rui Xu, Keshi Wang, James P Rizzi, Heli Huang, Jonas A Grina, Stephen T Schlachter, Bin Wang, Paul M Wehn, Hanbiao Yang, Darryl D Dixon, Robert M Czerwinski, Xinlin Du, Emily L Ged, Guangzhou Han, Huiling Tan, Tai Wong, Shanhai Xie, John A Josey, Eli M Wallace. 3-[(1S,2S,3R)-2,3-Difluoro-1-hydroxy-7-methylsulfonylindan-4-yl]oxy-5-fluorobenzonitrile (PT2977), a Hypoxia-Inducible Factor 2α (HIF-2α) Inhibitor for the Treatment of Clear Cell Renal Cell Carcinoma.
Journal of medicinal chemistry.
2019 08; 62(15):6876-6893. doi:
10.1021/acs.jmedchem.9b00719. [PMID: 31282155]